David Borg

7PUBLICATIONS
19CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Dec 05, 2024
Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial.

Daniel H Palmer, Richard Jackson, Christoph Springfeld

|Jun 09, 2021
T cells, B cells, and PD-L1 expression in esophageal and gastric adenocarcinoma before and after neoadjuvant chemotherapy: relationship with histopathological response and survival.

Maria Christina Svensson, Albin Lindén, Jakob Nygaard

|Apr 03, 2021
Development of a Novel Weighted Ranking Method for Immunohistochemical Quantification of a Heterogeneously Expressed Protein in Gastro-Esophageal Cancers.

Cathy E Richards, Katherine M Sheehan, Elaine W Kay

|Oct 01, 2019
Palliative short-course hypofractionated radiotherapy followed by chemotherapy in esophageal adenocarcinoma: the phase II PALAESTRA trial.

David Borg, Jan Sundberg, Eva Brun

|Oct 26, 2018
Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma.

David Borg, Anna H Larsson, Charlotta Hedner

|Nov 16, 2017
Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment.

Charlotta Hedner, David Borg, Björn Nodin

Pageof 2

Frequent Collaborators

1 joint publications

Cathy E Richards

1 joint publications

Joanna Fay

1 joint publications

Ann M Hopkins

1 joint publications

Maria Christina Svensson